Because we have determined that the cost of reporting on these measures outweighs the benefits of retaining them in these programs, it would place an undue burden on hospitals and ASCs to require reporting on these measures as we explore alternative approaches to implementing measures related to well-being and nutrition
Our online pharmacist is available Monday to Friday, 8am-4pm (AWST): Phone: 1800 418 429 SMS: +61 483 913 912 Email: [email protected]
Related products Related products Related products
Pharmaceutical development shifted focus to setmelanotide, a selective MC4R agonist, which received FDA approval in 2020 specifically for genetic obesity syndromes with POMC or leptin receptor deficiency
Establishment and characterization of a novel primary hepatocellular carcinoma cell line with metastatic ability in vivo
In December 2025, the Centers for Medicare and Medicaid Services announced the upcoming launch of the Medicare GLP-1 Bridge program